Success of NicOx glaucoma candidates welcome news for Pfizer

Article

Nitric oxide-donating derivatives of latanoprost for the treatment of glaucoma have been shown to successfully lower intraocular pressure (IOP) in preclinical studies.

Nitric oxide-donating derivatives of latanoprost for the treatment of glaucoma have been shown to successfully lower intraocular pressure (IOP) in preclinical studies.

The compounds, which are the result of a collaboration between NicOx and Pfizer in 2004, brought about a greater IOP lowering effect than latanoprost in two validated experimental models of raised IOP. In one of these models, a single topical 0.1% dose of latanoprost resulted in an 18% reduction of IOP compared with a 30% reduction achieved with an equimolar dose of the alternative compound.

The two companies have since signed a second agreement which grants Pfizer exclusive rights to apply NicOx' proprietary nitric oxide-donating technology across the field of ophthalmology.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.